Cargando…

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

Introduction: Dacomitinib is an epidermal growth factor receptor (EGFR) inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in the first line in patients with EGFR activating mutations. Dacomitinib is taken orally once daily at 45 mg with or without food, until dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Garcia, Ana, Tan, Weiwei, Li, Jerry, Haughey, May, Masters, Joanna, Hibma, Jennifer, Lin, Swan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238139/ https://www.ncbi.nlm.nih.gov/pubmed/32272733 http://dx.doi.org/10.3390/pharmaceutics12040330

Ejemplares similares

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
por: Fostvedt, Luke K., et al.
Publicado: (2022)

Do Proton Pump Inhibitors Decrease Calcium Absorption?
por: Hansen, Karen E, et al.
Publicado: (2010)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores
por: Farrell, Christopher P., et al.
Publicado: (2011)

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
por: Wedemeyer, Ralph-Steven, et al.
Publicado: (2014)

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2015)

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
por: Tamura, Shuzo, et al.
Publicado: (2018)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
por: Wilson, George D., et al.
Publicado: (2020)

Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry
por: Yamamoto, Yutaro, et al.
Publicado: (2019)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Continuous absorption pumping
por: Liburg, M Yu
Publicado: (1995)

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Drug-induced liver injury associated with dacomitinib: A case report
por: Wang, Xuanxuan, et al.
Publicado: (2022)

Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
por: Srivastava, Pratima
Publicado: (2012)

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
por: Takahashi, Toshiaki, et al.
Publicado: (2012)

Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach
por: Piscitelli, Joseph, et al.
Publicado: (2023)

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2021)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression
por: Cholin, Liza, et al.
Publicado: (2021)

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
por: Mok, Tony S., et al.
Publicado: (2020)

Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report
por: Qiao, Fei, et al.
Publicado: (2022)

Histomorphological and Immunohistochemical Study of Dacomitinib-Induced Ileal Mucositis in Rats with the Possible Protection by Baicalin
por: Kandeel, Samah, et al.
Publicado: (2022)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation
por: Attwa, Mohamed W., et al.
Publicado: (2018)

Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases
por: Räisänen, Laura, et al.
Publicado: (2023)

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
por: Lee, Ju-Eun, et al.
Publicado: (2023)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
por: Endersby, Raelene, et al.
Publicado: (2018)

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
por: Zugazagoitia, Jon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m59mnm3695e5gt9mu6bc6t5eg3